Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 1 - 100 |
| Updated: | 4/6/2019 |
| Start Date: | November 9, 2001 |
Expression of the Genome in Lymphoid Malignancies
This study will use genomics-based technology, such as DNA microarrays, to more precisely
diagnose subsets of lymphoma, leukemia and multiple myeloma patients. There have been many
attempts to classify lymphoid cancers in ways that will be useful for clinical diagnosis and
treatment. Although broad diagnostic categories have been reliably defined, patients within
each category have distinct clinical courses, suggesting that these classifications could be
further divided into molecular (genetic) subtypes. For example, 40 percent of patients with
diffuse large B-cell lymphoma achieve long-term disease remissions following combination
chemotherapy and are apparently cured, whereas the remaining 60 percent die from the disease.
Similarly, some patients with follicular lymphoma develop aggressive disease within a few
years of diagnosis, while others have stable disease over 10 to 20 years. Although the
distinctions in clinical course of these diseases are recognized, there are no studies to
determine the molecular (genetic) basis for this variability. This study will try to define
new molecular diagnostic categories in these diseases and correlate them with clinical
features, including treatment response, disease remission and overall survival following
chemotherapy.
This retrospective study will use clinical data and tissue samples from participating centers
in the Lymphoma/Leukemia Molecular Profiling Project LLMPP). New patients will not be
recruited for this study.
Biopsy materials, including fresh frozen or OTC-embedded lymphoma biopsy material, viably
frozen samples of peripheral blood cells from leukemia patients, and viably frozen samples of
bone marrow aspirates from multiple myeloma patients will be collected from pathologists
participating in the LLMPP. RNA and genomic DNA will be extracted from the tumor samples. A
variety of technologies will be used to characterize the genome of the cancer cells,
including lymphochip microarrays for array-based comparative genomic hybridization; Southern
blotting and PCR for translocation of genes previously implicated in these malignancies; and
PCR and DNA sequencing methods for analyzing base changes in the genome of the cancer cells.
Clinical information from the initial diagnosis to disease relapse will be taken from
existing databases and/or patient charts. Gene expression will be correlated with the
clinical data. If a small number of genes is found to strongly predict clinical outcome,
quantitative RT-PCR assays using the Taqman technology may be developed as an alternative to
DNA microarray analysis.
diagnose subsets of lymphoma, leukemia and multiple myeloma patients. There have been many
attempts to classify lymphoid cancers in ways that will be useful for clinical diagnosis and
treatment. Although broad diagnostic categories have been reliably defined, patients within
each category have distinct clinical courses, suggesting that these classifications could be
further divided into molecular (genetic) subtypes. For example, 40 percent of patients with
diffuse large B-cell lymphoma achieve long-term disease remissions following combination
chemotherapy and are apparently cured, whereas the remaining 60 percent die from the disease.
Similarly, some patients with follicular lymphoma develop aggressive disease within a few
years of diagnosis, while others have stable disease over 10 to 20 years. Although the
distinctions in clinical course of these diseases are recognized, there are no studies to
determine the molecular (genetic) basis for this variability. This study will try to define
new molecular diagnostic categories in these diseases and correlate them with clinical
features, including treatment response, disease remission and overall survival following
chemotherapy.
This retrospective study will use clinical data and tissue samples from participating centers
in the Lymphoma/Leukemia Molecular Profiling Project LLMPP). New patients will not be
recruited for this study.
Biopsy materials, including fresh frozen or OTC-embedded lymphoma biopsy material, viably
frozen samples of peripheral blood cells from leukemia patients, and viably frozen samples of
bone marrow aspirates from multiple myeloma patients will be collected from pathologists
participating in the LLMPP. RNA and genomic DNA will be extracted from the tumor samples. A
variety of technologies will be used to characterize the genome of the cancer cells,
including lymphochip microarrays for array-based comparative genomic hybridization; Southern
blotting and PCR for translocation of genes previously implicated in these malignancies; and
PCR and DNA sequencing methods for analyzing base changes in the genome of the cancer cells.
Clinical information from the initial diagnosis to disease relapse will be taken from
existing databases and/or patient charts. Gene expression will be correlated with the
clinical data. If a small number of genes is found to strongly predict clinical outcome,
quantitative RT-PCR assays using the Taqman technology may be developed as an alternative to
DNA microarray analysis.
Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of
the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the
clinical courses and responses of patients to therapy are variable, suggesting that the
existing diagnostic categories may harbor more than one disease entity. Recent genomic
technologies allow a comprehensive molecular analysis of the expression of the genome in
cancer cells. DNA microarray analysis of gene expression in lymphomas revealed distinct
molecular subtypes of diffuse large B-cell lymphoma and these new molecularly-defined
lymphoma subtypes had divergent clinical outcomes. To extend our genomic analysis to all
lymphoid malignancies, we have formed a consortium of cooperating institutions termed the
Lymphoma/Leukemia Molecular Profiling Project (LLMPP). The clinical centers participating in
the LLMPP will send de-identified lymphoma, leukemia and multiple myeloma samples to the NCI
for gene expression profiling, array-based comparative genomic hybridization and cancer gene
resequencing. An additional site, The National Cancer Center Singapore, will send
de-identified samples of tumor tissue from patients with lymphoma.
Objective:
Assess gene expression on a genomic scale in lymphoma, leukemia and multiple myeloma samples
and its relationship to somatic genetic alterations.
Eligibility:
Diagnosis of lymphoid malignancy at one of the LLMPP participating institutions, including
specimens originating at other clinical sites and submitted to LLMPP participating sites or
The National Cancer Center Singapore.
Design:
This is an entirely retrospective study. All tumor biopsies containing malignant cells to be
analyzed were obtained previously from patients diagnosed and/or treated at one of the
institutions participating in the LLMPP or at The National Cancer Center Singapore.
Clinical data will also be sent for the patients in this study for the purpose of correlating
gene expression measurements with clinical outcome. The goals of this effort are to define
new molecular diagnostic categories in these diseases that are clinically relevant and to
gain new insight into the molecular pathways that are active in these malignancies.
The home institutions providing clinical data and tissue samples have obtained local approval
by their clinical research committees for this study.
the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the
clinical courses and responses of patients to therapy are variable, suggesting that the
existing diagnostic categories may harbor more than one disease entity. Recent genomic
technologies allow a comprehensive molecular analysis of the expression of the genome in
cancer cells. DNA microarray analysis of gene expression in lymphomas revealed distinct
molecular subtypes of diffuse large B-cell lymphoma and these new molecularly-defined
lymphoma subtypes had divergent clinical outcomes. To extend our genomic analysis to all
lymphoid malignancies, we have formed a consortium of cooperating institutions termed the
Lymphoma/Leukemia Molecular Profiling Project (LLMPP). The clinical centers participating in
the LLMPP will send de-identified lymphoma, leukemia and multiple myeloma samples to the NCI
for gene expression profiling, array-based comparative genomic hybridization and cancer gene
resequencing. An additional site, The National Cancer Center Singapore, will send
de-identified samples of tumor tissue from patients with lymphoma.
Objective:
Assess gene expression on a genomic scale in lymphoma, leukemia and multiple myeloma samples
and its relationship to somatic genetic alterations.
Eligibility:
Diagnosis of lymphoid malignancy at one of the LLMPP participating institutions, including
specimens originating at other clinical sites and submitted to LLMPP participating sites or
The National Cancer Center Singapore.
Design:
This is an entirely retrospective study. All tumor biopsies containing malignant cells to be
analyzed were obtained previously from patients diagnosed and/or treated at one of the
institutions participating in the LLMPP or at The National Cancer Center Singapore.
Clinical data will also be sent for the patients in this study for the purpose of correlating
gene expression measurements with clinical outcome. The goals of this effort are to define
new molecular diagnostic categories in these diseases that are clinically relevant and to
gain new insight into the molecular pathways that are active in these malignancies.
The home institutions providing clinical data and tissue samples have obtained local approval
by their clinical research committees for this study.
- INCLUSION CRITERIA:
Diagnosis of lymphoid malignancy at one of the LLMPP participating institutions, including
specimens originating at other clinical sites and submitted to LLMPP participating sites or
National Cancer Center Singapore.
Informed consent for research studies performed on biopsy material or waiver of the
requirement for informed consent by the clinical research review boards at the LLMPP
institutions or National Cancer Center Singapore.
Sufficient frozen biopsy and/or FFPE material from initial biopsy and/or biopsies at
relapse of disease to obtain adequate RNA and DNA for gene expression profiling and
analysis of genomic alterations in the malignant cells.
We found this trial at
1
site
9609 Medical Center Drive
Bethesda, Maryland 20892
Bethesda, Maryland 20892
1-800-422-6237
Phone: 301-435-8525
National Cancer Institute , 9000 Rockville Pike The National Cancer Institute (NCI) is part of...
Click here to add this to my saved trials
